[Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
Today is actively discussing the impact of the new adipocytokin visfatin on the processes of atherosclerosis and inflammation. In this regard, of particular interest is a contingent of patients with hypertension in combination with abdominal obesity (AO). According to the patient should receive an adequate selection of antihypertensive therapy in connection with common pathology. The aim of the study was improved the treatment of hypertensive patients combined with abdominal obesity, which based on determining the level of visfatin and markers of immune inflammation. There were 64 patients which separated on the 1st group of hypertensive patients (n=28), 2d hypertensive with AO (n=36) and the 3d group of 19 healthy individuals. Patients matched for age and sex. All patients were determined in serum the level of visfatin («RayBioteeh», USA) interleukin-6 (IL -6) ("Vector -Best", Russia) interleukin-4 (IL-4) ("Vector -Best ", Russian) and C -reactive protein (CRP) («DRG International Inc.», USA) - ELISA. The treatment was carrying out with a combination of antihypertensive therapy: angiotensin receptor blocker-II of olmesartan medoxomil (10-20 mg dose once daily) with a calcium antagonist amlodipine (5-10 mg once a day) as hypertensive patients with AO, and without. It was noted the achievement of target blood pressure in both groups. On the antihypertensive therapy the 1st group in serum the level of IL-6 and CRP was significantly decreased by 48.7% and 60,6% (p <0,05). Whereas in the 2nd group there were a statistically significant reduction in the level of IL-6 and CRP in serum by 43.6% and 63.4% and detected statistically significant change in the level of serum visfatin 37.3%, respectively (p <0,05). The level of IL-4 in serum was increased in the 1st and 2nd groups by 29.7% and 11.6%, respectively (p>0.05). Conducted combination of antihypertensive therapy reducing the level of visfatin in hypertensive patients with abdominal obesity. As well, as has contributed to the target blood pressure and reduce inflammation in both groups.